T-Cell Therapies for Epstein-Barr Virus–Associated Lymphomas

REFERENCES

• Cohen JI. Clinical aspects of Epstein-Barr virus infection. In: Robertson ES, ed. Epstein-Barr Virus. Norfolk, UK: Caister Academic Press; 2005:35–55.
   Google Scholar
• Kieff E. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins; 2007:2604–2654.
   Google Scholar
• Bollard CM, Cooper LJ, Heslop HE. Immunotherapy—targeting EBV-expressing lymphoproliferative diseases. Best Pract Res Clin Haematol. 2008;21:405–420.
   PubMed Web of Science ®Google Scholar
• Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. Lipincott Williams & Wilkins; 2007:2655–2700.
   Google Scholar
• God JM, Haque A. Burkitt lymphoma: pathogenesis and immune evasion. J Oncol. 2010;2010. pii: 516047. Epub 2010 Oct 5.
   PubMedGoogle Scholar
• Khanna R, Burrows SR, Steigerwald-Mullen PM, Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processing. Int Immunol. 1997;9:1537–1543.
   PubMedGoogle Scholar
• Heller KN, Upshaw J, Seyoum B, Distinct memory CD4+ T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers. Blood. 2007;109:1138–1146.
   PubMedGoogle Scholar
• Kuze T, Nakamura N, Hashimoto Y, The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV(+) and EBV(−) cases in Japanese population. Jpn J Cancer Res. 2000;91:1233–1240.
   PubMedGoogle Scholar
• Solomides CS, Miller AS, Christman RA, Lymphomas of the oral cavity: histology, immunologic type, and incidence of Epstein-Barr virus infection. Hum Pathol. 2002;33:153–157.
   PubMed Web of Science ®Google Scholar
• Ma L, Katz Y, Sharan KP, Epstein-Barr virus positive anaplastic large cell lymphoma: myth or reality? Int J Clin Exp Pathol. 2010;4:100–110.
   PubMedGoogle Scholar
• Herling M, Rassidakis GZ, Jones D, Absence of Epstein-Barr virus in anaplastic large cell lymphoma: a study of 64 cases classified according to World Health Organization criteria. Hum Pathol. 2004;35:455–459.
   PubMed Web of Science ®Google Scholar
• Kuze T, Nakamura N, Hashimoto Y, Clinicopathological, immunological and genetic studies of CD30+ anaplastic large cell lymphoma of B-cell type; association with Epstein-Barr virus in a Japanese population. J Pathol. 1996;180:236–242.
   PubMedGoogle Scholar
• Meijer CJ, Jiwa NM, Dukers DF, Epstein-Barr virus and human T-cell lymphomas. Semin Cancer Biol. 1996;7:191–196.
   PubMedGoogle Scholar
• Anagnostopoulos I, Hummel M, Stein H. Frequent presence of latent Epstein-Barr virus infection in peripheral T cell lymphomas. A review. Leuk Lymphoma. 1995;19:1–12.
   PubMed Web of Science ®Google Scholar
• Heslop HE. Biology and treatment of Epstein-Barr viurs associated non-Hodgkin's lymphomas. In: Hematology American Society Hematology Education Program 2005:260–266.
   PubMedGoogle Scholar
• Metzger M, Krasin MJ, Hudson MM, Onciu M. Hodgkin lymphoma. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2011:638–662.
   Google Scholar
• Brauninger A, Hansman ML, Strickler JG. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med. 1999;340:1239–1247.
   PubMedGoogle Scholar
• Pallesen G, Hamilton-Dutoit SJ, Expression of Epstein Barr virus late gene products in tumour cells of Hodgkin's disease. Lancet. 1991;337:320–322.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Bollard CM. Sobering realities of surviving Hodgkin lymphoma. Blood. 2011;117:1772–1773.
   PubMed Web of Science ®Google Scholar
• Kim JW, Kim BS, Bang SM, et al; on behalf of the Korean Society of Blood and Marrow Transplantation. Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation. Ann Hematol. Epub 2011 Apr 6.
   Google Scholar
• Wudhikarn K, Brunstein CG, Bachanova V, Relapse of Lymphoma after Allogeneic hematopoietic cell transplantation: management strategies and outcome. Biol Blood Marrow Transplant. 2011;17:1497–1504.
   PubMed Web of Science ®Google Scholar
• Bloor AJ, Thomson K, Chowdhry N, High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non- Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14:50–58.
   PubMed Web of Science ®Google Scholar
• Cavattoni I, Zabelina T, Ayuk F, Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation. Leuk Lymphoma. 2010;51:146–148.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Sureda A, Qian W, et al; UK and Spanish Collaborative Groups. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol. 2007;139:70–80.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Gottschalk S, Helen Huls M, Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma. Cytotherapy. 2011;13:518–522.
   PubMed Web of Science ®Google Scholar
• Roskrow MA, Suzuki N, Gan Y, Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 1998;91:2925–2934.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Aguilar L, Straathof KC, Cytotoxic T lymphocyte therapy for Epstein-Barr virus +Hodgkin's disease. J Exp Med. 2004;200:1623–1633.
   PubMed Web of Science ®Google Scholar
• Cho HI, Hong YS, Lee MA, Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas. Int J Hematol. 2006;83:66–73.
   PubMed Web of Science ®Google Scholar
• Sun Q, Burton R, Reddy V, Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br J Haematol. 2002;118:799–808.
   PubMed Web of Science ®Google Scholar
• Lucas KG, Salzman D, Garcia A, Sun Q. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer. 2004;100:1892–1901.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Gottschalk S, Leen AM, Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 2007;110:2838–2845.
   PubMed Web of Science ®Google Scholar
• Bollard CM, Dotti G, Gottschalk S, Administration of tumor-specific cytotoxic T lymphocytes engineered to resist TGF-β to patients with EBV-associated lymphomas. Blood (ASH Annual Meeting Abstracts). 2010;116:560.
   Google Scholar
• Fox CP, Haigh TA, Taylor GS, A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood. 2010;116:3695–3704.
   PubMedGoogle Scholar
• Heslop HE. How I treat EBV lymphoproliferation [review]. Blood. 2009;114:4002–4008.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Webber SA, Chadburn A, Ferry J. Post transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, eds. Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008:342–349.
   Google Scholar
• Gottschalk S, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disorders. Annu Rev Med. 2005;56:29–44.
   PubMed Web of Science ®Google Scholar
• Curtis RE, Travis LB, Rowlings PA, Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208–2216.
   PubMed Web of Science ®Google Scholar
• Kennedy-Nasser AA, Bollard CM, Heslop HE. Immunotherapy for Epstein-Barr virus-related lymphomas. Mediterr J Hematol Infect Dis. 2009;1:e2009010.
   PubMedGoogle Scholar
• Shiramizu B, Wilkinson R, Hayashi R. Lymphoproliferative disorders and malignancies related to immunodeficiencies. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 6th ed. Sixth Edition 2011. Philadelphia: Lippincott Williams & Wilkins; 683–702.
   Google Scholar
• Kuehnle I, Huls MH, Liu Z, CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000;95:1502–1505.
   PubMed Web of Science ®Google Scholar
• Faye A, Quartier P, Reguerre Y, Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol. 2001;115:112–118.
   PubMed Web of Science ®Google Scholar
• Skoda-Smith S, Douglas VK, Mehta P, Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001;27:329–332.
   PubMed Web of Science ®Google Scholar
• Comoli P, Basso S, Zecca M, Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant. 2007;7:1648–1655.
   PubMed Web of Science ®Google Scholar
• Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994;331:679–680.
   PubMed Web of Science ®Google Scholar
• O'Reilly RJ, Small TN, Papadopoulos E, Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev. 1997;157:195–216.
   PubMed Web of Science ®Google Scholar
• Bondanza A, Valtolina V, Magnani Z, Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood. 2006;107:1828–1836.
   PubMed Web of Science ®Google Scholar
• Bonini C, Bondanza A, Perna SK, The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol Ther. 2007;15:1248–1252.
   PubMed Web of Science ®Google Scholar
• Tey SK, Dotti G, Rooney CM, Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:913–924.
   PubMed Web of Science ®Google Scholar
• Heslop HE, Ng CYC, Li C, Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2:551–555.
   PubMed Web of Science ®Google Scholar
• Gustafsson A, Levitsky V, Zou JZ, Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood. 2000;95:807–814.
   PubMed Web of Science ®Google Scholar
• Comoli P, Basso S, Zecca M, Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant. 2007;7:1648–1655.
   PubMed Web of Science ®Google Scholar
• Melenhorst JJ, Leen AM, Bollard CM, Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010;116:4700–4702.
   PubMed Web of Science ®Google Scholar
• Heslop HE, Slobod KS, Pule MA, Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphproliferative diseases in transplant recipients. Blood. 2010;115:925–935.
   PubMed Web of Science ®Google Scholar
• Moosmann A, Bigalke I, Tischer J, Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood. 2010;115:2960–2970.
   PubMed Web of Science ®Google Scholar
• Uhlin M, Okas M, Gertow J, A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol Immunother. 2010;59:473–477.
   PubMed Web of Science ®Google Scholar
• Savoldo B, Goss JA, Hammer MM, Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006;108:2942–2949.
   PubMed Web of Science ®Google Scholar
• Comoli P, Labirio M, Basso S, Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood. 2002;99:2592–2598.
   PubMed Web of Science ®Google Scholar
• Khanna R, Bell S, Sherritt M, Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A. 1999;96:10391–10396.
   PubMed Web of Science ®Google Scholar
• Sherritt MA, Bharadwaj M, Burrows JM, Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation. 2003;75:1556–1560.
   PubMed Web of Science ®Google Scholar
• Brewin J, Mancao C, Straathof K, Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Blood. 2009;114:4792–4803.
   PubMed Web of Science ®Google Scholar
• De Angelis B, Dotti G, Quintarelli C, Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009;114:4784–4791.
   PubMed Web of Science ®Google Scholar
• Wilkie GM, Taylor C, Jones MM, Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of Epstein-Barr virus-associated diseases. J Immunother. 2004;27:309–316.
   PubMed Web of Science ®Google Scholar
• Haque T, Wilkie GM, Taylor C, Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet. 2002;360:436–442.
   PubMed Web of Science ®Google Scholar
• Haque T, Wilkie GM, Jones MM, Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110:1123–1131.
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Wilkie GM, Dua U, Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am J Transplant. 2007;7:1293–1299.
   PubMed Web of Science ®Google Scholar
• Barker JN, Doubrovina E, Sauter C, Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood. 2010;116:5045–5049.
   PubMed Web of Science ®Google Scholar
• Leen AM, Bollard CM, Mendizabal AM, Most closely HLA-matched allogeneic virus specific cytotoxic T-lymphocytes (CTL) to treat persistent reactivation or infection with adenovirus, CMV and EBV after hemopoietic stem cell transplantation (HSCT). Blood (ASH Annual Meeting Abstracts). 2010;116:829.
   PubMedGoogle Scholar